

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/349379441>

# Protein binding capacity of nanostructured lipid carriers loaded with Salvia off. extract

Conference Paper · January 2018

CITATIONS

0

READS

7

7 authors, including:



**Monika Kostovska**

Alkaloid

8 PUBLICATIONS 3 CITATIONS

[SEE PROFILE](#)



**Ljubica Mihailova**

Ss. Cyril and Methodius University in Skopje

21 PUBLICATIONS 15 CITATIONS

[SEE PROFILE](#)



**Dushko Shalabalija**

Ss. Cyril and Methodius University in Skopje

22 PUBLICATIONS 15 CITATIONS

[SEE PROFILE](#)



**Marija Glavas Dodov**

Ss. Cyril and Methodius University in Skopje

193 PUBLICATIONS 1,079 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Model framework for regulation of the use of registered drugs for unapproved uses and use of unregistered medicines, financed by Faculty of pharmacy, UKIM, Skopje [View project](#)



The role and activities of pharmacists in community pharmacies in R.N. Macedonia in the period of COVID-19 pandemic [View project](#)

## Protein binding capacity of nanostructured lipid carriers loaded with *Salvia off.* extract

E. Markova, M. Kostovska, L. Taneska, Lj. Cambuleva, D. Shalabalija, M.G. Dodov, M.S. Crcarevska

*Institute of pharmaceutical technology, Center of pharmaceutical nanotechnology, Faculty of pharmacy, Ss. Cyril & Methodius University, Majka Tereza 47, 1000 Skopje, R. Macedonia.*

*Email of presenting author: [elena.markova1@yahoo.com](mailto:elena.markova1@yahoo.com)*

Having in mind the current options for Alzheimer's disease (AD) treatment and its limitations on the one hand, and advantages and possibilities offered by drug delivery carriers (DDS) on the other hand, nanostructured lipid carriers (NLC) would be potentially efficient in AD treatment. One of the most important factors that influence DDS in vivo faith is their plasma protein binding capacity, critical for formation of protein corona that largely defines their biological identity [1]. Understanding the influence of formulation composition and DDS physico-chemical properties upon affinity for protein corona formation might significantly contribute to development of new innovative functional therapies in AD. NLC loaded with freeze-dried *Salvia off.* methanolic extract (FSE) were formulated using solvent evaporation method previously described [2]. Phospholipon 90H (Phospholipid, Germany) and oleic acid (Sigma-Aldrich, Germany) were used as lipid phase (1:0.43). Ratio of total lipid to ethanol as organic solvent was 1:20, while total lipid to Tween 80 (Merck, Germany) ratio was 1:0.47, 1:0.84 and 1:1.16 for NLC-FSE5, NLC-FSE6 and NLC-FSE 7, respectively. Organic solvent with 0.58% FSE to water phase (0.5% Poloxamer 407, BASF, Germany) ratio was 1:2. Prepared formulations were characterized in terms of particle size and zeta potential (Zetasizer nano ZS, Malvern, UK). Protein binding capacity was determined by protein adsorption studies [3]. Obtained results indicated that by increasing the amount of surfactant (Tween 80) the particle size decreased (from  $236\pm 4$  to  $132\pm 3$  nm) probably due to the lower surface tension thus resulting with smaller NLC-FSE. Zeta potential values were in a range of  $-10\pm 2.1$  to  $-18\pm 2.8$  mV. At the same time protein binding capacity increased (from  $33.74\pm 3.2$  to  $50.76\pm 4.1\%$ ), most likely due to the larger surface area exposed to the proteins as well as zeta potential values.

- 
1. D. Dutta, S.K. Sundaram, J.G. Teeguarden, B.J. Riley, L.S. Fifield, J.M. Jacobs, S.R. Addleman, G.A. Kaysen, B.M. Moudgil, T.J. Weber, *Toxicol. Sci.*, **2007**, *100*,303.
  2. L. Taneska, M. Kostovska, E. Markova, Lj. Cambuleva, D. Shalabalija, M.G. Dodov, I.C. Karanfilova, M. Petrushevska, R.S. Raicki, M.S. Crcarevska. Abstract book of 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spain, **2018**.
  3. M. Simonoska Crcarevska, N. Geskovski, S. Calis, S. Dimcevska, S. Georgievska, Gj. Petruševski, M. Kajžanoska, Sonja Ugarkovic, K. Goracinova, *Eur. J. Pharm. Sci.*, **2013**, *49(1)*, 65.